Perrigo (NYSE:PRGO) Issues FY 2026 Earnings Guidance

Perrigo (NYSE:PRGO) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 2.250-2.550 for the period, compared to the consensus earnings per share estimate of 2.700. The company issued revenue guidance of $4.0 billion-$4.2 billion, compared to the consensus revenue estimate of $4.2 billion.

Perrigo Stock Down 1.3%

Shares of NYSE:PRGO opened at $14.41 on Thursday. Perrigo has a fifty-two week low of $12.17 and a fifty-two week high of $30.93. The firm’s 50 day moving average price is $14.39 and its 200 day moving average price is $17.57. The company has a quick ratio of 1.44, a current ratio of 2.51 and a debt-to-equity ratio of 0.81. The stock has a market cap of $1.98 billion, a price-to-earnings ratio of -37.93, a price-to-earnings-growth ratio of 1.31 and a beta of 0.39.

Perrigo Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 24th. Stockholders of record on Monday, March 2nd will be given a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a dividend yield of 8.0%. The ex-dividend date is Monday, March 2nd. Perrigo’s payout ratio is currently -305.26%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. JPMorgan Chase & Co. reduced their price target on shares of Perrigo from $20.00 to $18.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Argus raised shares of Perrigo to a “hold” rating in a report on Wednesday, January 14th. Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a report on Friday, February 13th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Perrigo in a research report on Monday, December 22nd. Finally, Canaccord Genuity Group cut their price target on shares of Perrigo from $40.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, November 6th. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Perrigo presently has an average rating of “Hold” and an average price target of $20.33.

Institutional Trading of Perrigo

Institutional investors have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. lifted its position in Perrigo by 35.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,386,111 shares of the company’s stock valued at $19,295,000 after purchasing an additional 363,501 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Perrigo by 134.2% in the 4th quarter. Invesco Ltd. now owns 4,542,415 shares of the company’s stock worth $63,230,000 after purchasing an additional 2,602,724 shares in the last quarter. Corient Private Wealth LLC acquired a new stake in Perrigo during the fourth quarter valued at approximately $283,000. Vident Advisory LLC raised its position in shares of Perrigo by 7.0% during the fourth quarter. Vident Advisory LLC now owns 51,098 shares of the company’s stock worth $711,000 after purchasing an additional 3,350 shares during the period. Finally, First Citizens Bank & Trust Co. lifted its holdings in shares of Perrigo by 126.3% during the fourth quarter. First Citizens Bank & Trust Co. now owns 39,207 shares of the company’s stock valued at $546,000 after purchasing an additional 21,884 shares during the last quarter. Institutional investors own 95.91% of the company’s stock.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.